摘要
痴呆是一种以认知功能缺损为核心症状的获得性智能损害综合症,属于慢性进展性疾病,严重影响患者的生活质量。导致痴呆的疾病中阿尔茨海默病(AD)占3/4,其余还包括血管性痴呆(VaD)、混合型痴呆、路易体痴呆、额颞叶痴呆等。AD已成为影响我国经济社会发展的重大公共卫生健康问题和社会问题,但目前为止,获得批准治疗AD的药物只有胆碱酯酶抑制剂和NMDA受体拮抗剂两类,这些药物只能控制症状,而无法达到疾病修饰治疗(DMT)的效果。此外,国外最近十年被批准进行的AD临床实验较少,且失败率较高,目前尚未开发出具有DMT效果的AD治疗药物。本文从AD相关的神经退行性病理变化、AD相关临床实验研究作一综述,为开发新的AD治疗靶点提供参考依据。
Dementia is an acquired mental impairment syndrome with cognitive impairment as its core symptom.It is a chronic progressive disease that seriously affects the quality of life of patients.Alzheimer's disease(AD)accounts for 3/4 of the diseases that cause dementia.The rest also include vascular dementia(VaD),mixed dementia,Lewy body dementia,frontotemporal dementia,and so on.AD has become a major public health health issue and social issue that affects China's economic and social development,but so far,the only drugs approved for treating AD are cholinesterase inhibitors and NMDA receptor antagonists.These drugs can only control symptoms,And can not achieve the effect of disease modification treatment(DMT).In addition,few AD clinical trials have been approved in foreign countries in the last ten years,and the failure rate is high.At present,no AD treatment drug with DMT effect has been developed.This article reviews the AD-related neurodegenerative pathological changes and AD-related clinical experimental research,and provides a reference basis for the development of new AD treatment targets.
作者
杨联勇
沈金娥
YANG Lian-yong;SHEN Jin-e(Department of Geriatric Psychiatry,Yunnan Provincial Psychiatric Hospital,Kunming 650224,Yunnan,China)
出处
《医学信息》
2020年第2期50-52,共3页
Journal of Medical Information
